anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To enhance the affinity for bone tissure and to improve the workability by successively forming an underlayer and a coating layer each contg. a calcium phosphate compound as the principal component on the surface of a Ti material and by modifying the coating layer by hydrothermal treatment. CONSTITUTION:The surface of a Ti (alloy) material is activated and a soln. prepd. by dissolving a calcium phosphate compound such as tricalcium phosphate in an aqueous soln. of hydrochloric acid or nitric acid is applied to the activated surface and baked by heating to form a rigid underlayer. A suspension prepd. by dispersing the calcium phosphate compound in an aqueous soln. of hydrochloric acid or the like is applied to the underlayer and sintered by heating to form a coating layer. This coating layer is modified by hydrothermal treatment to increase the degree of crystallinity. The resulting composite Ti material coated with the calcium phosphate compound is light in weight and has satisfactory mechanical strength, so it is suitable for use as an implant material such as an artifical bone or an artifical dental root.
Adult Patients

A US multicenter, double-blind, placebo-controlled study of pantoprazole sodium 10 mg, 20 mg, or 40 mg once daily was conducted in 603 patients with reflux symptoms and endoscopically diagnosed EE of grade 2 or above (Hetzel-Dent scale). In this study, approximately 25% of enrolled patients had severe EE of grade 3, and 10% had grade 4. The percentages of patients healed (per protocol, n = 541) in this study are shown in Table 8.

In this study, all pantoprazole sodium treatment groups had significantly greater healing rates than the placebo group. This was true regardless of H. pylori status for the 40 mg and 20 mg pantoprazole sodium treatment groups. The 40 mg dose of pantoprazole sodium resulted in healing rates significantly greater than those found with either the 20 mg or 10 mg dose.

A significantly greater proportion of patients taking pantoprazole sodium 40 mg experienced complete relief of daytime and nighttime heartburn and the absence of regurgitation, starting from the first day of treatment, compared with placebo. Patients taking pantoprazole sodium consumed significantly fewer antacid tablets per day than those taking placebo.

Pantoprazole sodium 40 mg and 20 mg once daily were also compared with nizatidine 150 mg twice daily in a US multicenter, double-blind study of 243 patients with reflux symptoms and endoscopically diagnosed EE of grade 2 or above. The percentages of patients healed (per protocol, n = 212) are shown in Table 9.

Once-daily treatment with pantoprazole sodium 40 mg or 20 mg resulted in significantly superior rates of healing at both 4 and 8 weeks compared with twice-daily treatment with 150 mg of nizatidine. For the 40 mg treatment group, significantly greater healing rates compared to nizatidine were achieved regardless of the H. pylori status.

A significantly greater proportion of the patients in the pantoprazole sodium treatment groups experienced complete relief of nighttime heartburn and regurgitation, starting on the first day and of daytime heartburn on the second day, compared with those taking nizatidine 150 mg twice daily. Patients taking pantoprazole sodium consumed significantly fewer antacid tablets per day than those taking nizatidine.

Pediatric Patients Ages 5 Years through 16 Years

The efficacy of pantoprazole sodium in the treatment of EE associated with GERD in pediatric patients ages 5 years through 16 years is extrapolated from adequate and well-conducted trials in adults, as the pathophysiology is thought to be the same. Four pediatric patients with endoscopically diagnosed EE were studied in multicenter, randomized, double-blind, parallel-treatment trials. Children with endoscopically diagnosed EE (defined as an endoscopic Hetzel-Dent score ≥ 2) were treated once daily for 8 weeks with one of two dose levels of pantoprazole sodium (20 mg or 40 mg). All 4 patients with EE were healed (Hetzel-Dent score of 0 or 1) at 8 weeks.
To provide a neck diagnostic device and a program.SOLUTION: A neck diagnostic device 100 utilizing an artificial intelligence (AI) 40 of the present invention comprises: a camera 1; a teacher data part 50; a training part 60; a diagnosing part 70; and a display 2. The camera 1 captures, a learning moving image and a diagnostic moving image including a motion of an infant who is subjected to examination of traction response. The teacher data part 50 preserves the teacher data which is generated by a medical specialist, by partitioning a rectangular region so as to include a required region which is required for diagnosis of presence of a reflex motion in the learning moving image, partitioning a time region including a motion required for diagnosis, then diagnosing presence of the reflex motion on the basis of the motion in the rectangular region of the time region, then associating the motion with a diagnosis result. The training part 60 causes an AI 40 to machine learn the teacher data. The diagnosing part 70 causes the AI 40 which performed machine learning of the teacher data to diagnosis presence/absence of the reflex motion of the diagnostic moving image for acquiring AI diagnosis. The display 2 displays the AI diagnosis.SELECTED DRAWING: Figure 3
Obesity is a global health concern. Recent research has suggested that the development of anti-obesity ingredients and functional foods should focus on natural products without side effects. We examined the effectiveness and underlying mechanisms of Brassica juncea extract (BJE) in combating obesity via experiments conducted in both in vitro and in vivo obesity models. In in vitro experiments conducted in a controlled environment, the application of BJE demonstrated the ability to suppress the accumulation of lipids induced by MDI in 3T3-L1 adipocytes. Additionally, it downregulated adipogenic-related proteins peroxisome proliferator-activated receptor-γ (PPAR-γ), CCAAT/enhancer-binding protein-α (C/EBP-α), adipocyte protein 2 (aP2), and lipid synthesis-related protein acetyl-CoA carboxylase (ACC). It also upregulated the heat generation protein peroxisome proliferator-activated receptor gamma coactivator-1α (PGC-1α) and fatty acid oxidation protein carnitine palmitoyltransferase-1 (CPT-1). The oral administration of BJE decreased body weight, alleviated liver damage, and inhibited the accumulation of lipids in mice with diet-induced obesity resulting from a high-fat diet. The inhibition of lipid accumulation by BJE in vivo was associated with a decreased expression of adipogenic and lipid synthesis proteins and an increased expression of heat generation and fatty acid oxidation proteins. BJE administration improved obesity by decreasing adipogenesis and activating heat generation and fatty acid oxidation in 3T3-L1 cells and in HFD-induced obese C57BL/6J mice. These results suggest that BJE shows potential as a natural method for preventing metabolic diseases associated with obesity.
Participants in this group will continue to receive standard care without access to the Mission is Remission® website. They will also be emailed a link to complete online questionnaires. At the end of the 6 month study period, participants in this group will be given access to the study website.
A device for administering fluid compositions includes a housing having a first end with an opening. The housing includes a compartment, proximate to the first end, that is capable of holding a liquid reservoir that is at least partially filled with a fluid. The device includes an air pump positioned within the housing, at a second end. The device includes an actuator positioned between the compartment and the air pump. The actuator includes an extendible piston that is configured to extend laterally toward the compartment. During device operation, the actuator causes the piston to extend towards the liquid reservoir and exert a force on the liquid reservoir. The force causes the fluid to be expelled from the liquid reservoir at the first end. The air pump is configured to atomize the fluid at the first end as it is expelled from the liquid reservoir.
BACKGROUND: Perioperative myocardial injury after noncardiac surgery is associated with postoperative mortality. Heart rate (HR) is an independent risk factor for perioperative myocardial injury. In this pilot trial we tested the feasibility of a randomised, placebo-controlled trial of personalised HR-targeted perioperative ivabradine.
METHODS: This was a single-centre, randomised, placebo-controlled, double-blind, parallel group, feasibility pilot trial conducted at Geneva University Hospitals. We included patients ≥75 yr old or ≥45 yr old with cardiovascular risk factors planned for intermediate- or high-risk surgery. Patients were randomised to receive ivabradine (2.5, 5.0, or 7.5 mg) or placebo according to their HR, twice daily, from the morning of surgery until postoperative day 2. Primary outcomes were appropriate dosage and blinding success rates.
RESULTS: Between October 2020 and January 2022, we randomised 78 patients (recruitment rate of 1.3 patients week-1). Some 439 of 444 study drug administrations were adequate (99% appropriate dosage rate). The blinding success rate was 100%. There were 137 (31%) administrations of Pill A (placebo in both groups for HR ≤70 beats min-1). Nine (11.5%) patients had a high-sensitive cardiac troponin T elevation ≥14 ng L-1 between any two measurements. The number of bradycardia episodes was eight in the placebo group and nine in the ivabradine group.
CONCLUSIONS: This pilot study demonstrates the feasibility of, and provides guidance for, a future trial testing the efficacy of personalised perioperative ivabradine. Future studies should include patients at higher risk of cardiac complications.
CLINICAL TRIAL REGISTRATION: NCT04436016.
We will conduct a parallel-group, double-blind randomized trial at Stanford Bay Area and Chicago sites, identifying 160 participants with a prominent clinical cognitive signature (C+) and relative absence of the signature (C-). We will enrich for C+, the signature of interest, at a 2:1 ratio. Participants will be randomly assigned to receive guanfacine (shown to ameliorate cognitive control deficits in our preliminary data) plus sertraline or placebo plus sertraline.
Skin and soft tissue infections-cellulitis, furuncles, carbuncles, and abscesses-make up approximately 1-2% of emergency room visits annually. While abscesses are generally incised and drained, there is no definite standard treatment regimen or duration of treatment that practitioners have adhered to regarding antibiotic use. Historical evidence suggests that antibiotics may not be necessary for simple superficial abscesses, though a number of antibiotics-including penicillins and cephalosporins-may be used for treatment of large and/or complicated abscesses. These antibiotics however are ineffective against what is becoming an increasingly common pathogen- community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA).

At our institution, it is estimated that 60-70% (unpublished observation) of cultured abscesses are caused by CA-MRSA. These patients have generally been treated with incision and drainage, with the addition of an antibiotic left to the practitioner's discretion. Also, there has been no universally accepted duration of treatment established to observe clinical improvement of such abscesses. Common antibiotic regimens range from 7-14 days of treatment for cellulitic infections. While there has been one prospective trial regarding the use of antibiotics in simple abscesses, there has been no published prospective study on the use of antibiotics in treating CA-MRSA abscesses in adults. Furthermore, while 7-14 days of treatment seems the recommended duration of treating cellulitic infections, no study has evaluated the duration of treatment needed to observe clinical improvement of abscesses caused by CA-MRSA. We wish to prospectively evaluate the duration of treatment necessary to observe clinical improvement of abscesses caused by CA-MRSA among multiple different antibiotics (ie. cephalexin, clindamycin, and trimethoprim/sulfamethoxazole) after standard incision and drainage in patients presenting to the emergency department.
OBJECTIVE: Hypertriglyceridemic waist (HW), hypertriglyceridemic waist-to-height ratio (HWHtR), and waist-to-hip ratio (WHR) have been shown to be indicators of cardiometabolic risk factors. However, it is not clear which indicator is more suitable for children and adolescents. We aimed to investigate the relationship between HW, HWHtR, WHR, and cardiovascular risk factors clustering to determine the best screening tools for cardiometabolic risk in children and adolescents.
METHODS: This was a national cross-sectional study. Anthropometric and biochemical variables were assessed in approximately 70,000 participants aged 6-18 years from seven provinces in China. Demographics, physical activity, dietary intake, and family history of chronic diseases were obtained through questionnaires. ANOVA, χ 2 and logistic regression analysis was conducted.
RESULTS: A significant sex difference was observed for HWHtR and WHR, but not for HW phenotype. The risk of cardiometabolic health risk factor clustering with HW phenotype or the HWHtR phenotype was significantly higher than that with the non-HW or non-HWHtR phenotypes among children and adolescents (HW: OR = 12.22, 95% CI: 9.54-15.67; HWHtR: OR = 9.70, 95% CI: 6.93-13.58). Compared with the HW and HWHtR phenotypes, the association between risk of cardiometabolic health risk factors (CHRF) clustering and high WHR was much weaker and not significant (WHR: OR = 1.14, 95% CI: 0.97-1.34).
CONCLUSION: Compared with HWHtR and WHR, the HW phenotype is a more convenient indicator withhigher applicability to screen children and adolescents for cardiovascular risk factors.
Subjects randomized to control will receive additional dural sutures as deemed necessary by the surgeon. CSF leakage will be re-evaluated with the Valsalva maneuver to 10-20 cm H2O for 5 to 10 seconds. Closure of the remaining layers of the surgical site will be performed according to the surgeon's standard of practice.
Lantus® solution for subcutaneous injection, 100 U/mL, in the SoloStar® 3.0 mL prefilled insulin pen. Subjects randomized to the Lantus® group will participate for 26 weeks.
A method for forming encapsulated gold nanoparticles mixes mangiferin into a liquid medium to form a reducing agent solution. Gold salts are mixed into the reducing agent solution. Reaction of the gold salts is permitted, in the absence of any other reducing agent, to form a nanoparticle solution of stabilized, biocompatible gold nanoparticles coated with mangiferin. The gold salts can consist of AuCl4, or can consist of radioactive gold salts. A cancer therapy method injects a solution of mangiferin encapsulated gold nanoparticles directly into a solid tumor. A solution consisting of an aqueous or alcoholic medium and mangiferin encapsulated gold nanoparticles is provided. The mangiferin encapsulated gold nanoparticles can have core sizes of ~5-20nm and total sizes of ~20-120nm.
In plane posterior approach will be used with a 50mm short bevel block needle (Braun), advanced through the middle scalene muscle. At the location chosen for interscalene block the needle tip will be positioned anterior to the anterior scalene muscle. At this point 10ml of 0.9% saline will be injected. This will be followed by repositioning of the needle between roots C5 and C6 where 20 ml of 0.25% levobupivicaine will be injected in 5ml increments with intermittent aspiration.
Smartphone application for more continuous but less structured chat support. This app was recognized by the American Diabetes Association. The intervention included access to online diabetes support tools and ability to message a diabetes specialist for support, and 3 and 6-month follow-ups.
The fresh excision breast cancer tissues were completely soaked in the ICG-SG incubation solution for about 10 minutes, followed by 5 minutes of rinsing with PBS buffer and drying with the use of absorbent paper. Then fluorescence imaging was performed with the DPM NIR-II system. And the result was analyzed to identify the tumor area and distinguish the tumor boundary.
HPV16 is responsible for approximately 60% and 90% of global HPV-induced cervical and oropharyngeal cancers, respectively. HPV16 intratype variants have been identified by HPV genome sequencing and classified into four phylogenetic lineages (A-D). Our understanding of HPV16 variants mostly derives from epidemiological studies on cervical cancer (CC) in which HPV16 B, C, and D lineages (previously named "non-European" variants) were mainly associated with high-grade cervical lesions and cancer. Although a predominance of HPV16 lineage A (previously named "European variants") has been observed in head and neck squamous cell carcinoma (HNSCC), epidemiological and in vitro biological studies are still limited for this tumor site. Next Generation Sequencing (NGS) of the entire HPV genome has deepened our knowledge of the prevalence and distribution of HPV variants in CC and HNSCC. Research on cervical cancer has shown that certain HPV16 sublineages, such as D2, D3, A3, and A4, are associated with an increased risk of cervical cancer, and sublineages A4, D2, and D3 are linked to a higher risk of developing adenocarcinomas. Additionally, lineage C and sublineages D2 or D3 of HPV16 show an elevated risk of developing premalignant cervical lesions. However, it is still crucial to conduct large-scale studies on HPV16 variants in different HPV-related tumor sites to deeply evaluate their association with disease development and outcomes. This review discusses the current knowledge and updates on HPV16 phylogenetic variants distribution in HPV-driven anogenital and head and neck cancers.
Placebo-matching ciclesonide, inhaled via a MDI with HFA-134a as propellant, once daily, in the evening for 2 to 4 weeks in the Baseline period followed by ciclesonide 80 µg, inhaled via a MDI with HFA-134a as propellant, once daily in the evening for 12 weeks. Salbutamol 100 μg/puff was available to be used as rescue medication if needed.
The unsaturated fatty acids eicosatetraenoic acid (20:4, omega 6) and eicosapentaenoic acid (20: 5, omega 3) play an extremely important role in human fat metabolism; from them are formed the metabolites prostaglandins and leucotrienes, present in every cell, which are essential for normal cell function. Eicosapentaenoic acid principally occurs in fish or fish products. A diet rich in eicosapentaenoic acid has a favourable effect on specific diseases from the prophylactic and therapeutic aspect. The supply necessary for this purpose of a considerable amount of fish or fish oil is associated with severe disadvantages such as low stability, part being in the liquid form, digestion and taste disturbance, increased supply of cholesterol and triglycerols which contain fatty acids other than eicosapentaenoic acid. alpha -Linolenic acid (18:3, omega 3) which occurs in linseed oil and other crops, is metabolised in the body to give eicosapentaenoic acid. The disadvantages of the fish diet can be avoided, retaining the same action, by using linseed oil and other  alpha -linolenic acid-containing crops. The  alpha -linolenic acid present in the linseed oil or in other crops can be isolated and then used itself, or better as a derivative, e.g. as the magnesium salt of  alpha -linolenic acid; oral intake thus becomes significantly simpler and the taste is more pleasant. Linseed and linseed oil and the other... Original abstract incomplete.
PURPOSE: To provide both electro-chemical battery characteristics containing a liquid electrolyte and electrochemical battery characteristics containing a solid electrolyte by directly disposing at least one kind of ion exchange membrane on one front face of diffusion electrodes between diffusion electrodes. CONSTITUTION: An electro-chemical battery 1, for example, a fuel cell comprises diffusion electrodes 2 and 3. The diffusion electrode 3 has an ion exchange film 4. The ion exchange membrane 4 may be a polymer substance having a functional group such as a sulfonic group, a carboxyl group, or a tertiary amine. It is advantageous that the diffusion electrode 3 and the ion exchange membrane 4 are rigidly coupled with each other. Alternatively, it is advantageous that the ion exchange membrane 4 surrounds an active catalyst.
A topical use pharmaceutical composition and a process for its preparation, comprising an improved enzyme-modified casein sol. Prior to being enzyme-modified, the casein is solubilized and neutralized by an alkali solution containing a molar weight percent ratio in the range of from 90:10 to 100:0, potassium hydroxide to sodium hydroxide. Said neutralization occurring for a time in the range of 5 to 35 minutes to allow for complete neutralization of the casein. The neutralized casein is then hydrolyzed or modified by enzymatic digestion by a proteolytic enzyme for a time sufficient to achieve a weight ratio of protein nitrogen to amino nitrogen in the range from 7:1 to 9:1. The improved enzyme-modified casein sol may then be mixed with stabilizing and pressuring agents, such as carrageenan, polyvinyl pyrrolidone, methyl paraben or propyl paraben. Topical uses for the improved enzyme-modified casein composition include healing and relieving infections, wounds, burns, dermatitis, skin eruptions, dandruff, hemorrhoids and bruises.
The prevention and management of cancer therapy-related cardiac dysfunction (CTRCD) have become increasingly important. Recent studies have revealed the crucial role of genetics in determining the susceptibility to development of CTRCD. We present a case of a 65-year-old woman with breast cancer who developed recurrent CTRCD following low-dose chemotherapy, despite lacking conventional cardiovascular risk factors. Her medical history included anthracycline-associated cardiomyopathy, and her condition deteriorated significantly after treatment with HER2-targeted therapies. Through the use of multimodal imaging, we detected severe left ventricular systolic dysfunction. Further investigation with genetic testing revealed a likely pathogenic variant in the TNNT2 gene, suggesting a genetic predisposition to CTRCD. This case implies the potential role of genetic screening in identifying patients at risk for CTRCD and advocates for personalized chemotherapy and cardioprotective strategies.
PCT No. PCT/SE83/00190 Sec. 371 Date Jan. 5, 1984 Sec. 102(e) Date Jan. 5, 1984 PCT Filed May 10, 1983 PCT Pub. No. WO83/04054 PCT Pub. Date Nov. 24, 1983.A method of determining dTk isoenzyme levels of a human or animal body fluid or cell sample is disclosed, which comprises the steps of reacting said sample with a substrate for said isoenzyme in the presence of a phosphate donor and a buffer system, and measuring the amount of phosphorylated product formed, said amount being proportional to said isoenzyme level. The method is characterized by using in combination (a) a buffer system at pH ranging from 5 to 9 and being present in a concentration of no more than 250 mM, (b) a substrate consisting of 2'-deoxy-5-halouridin, part of which has a radio-labelled 5-halogen, and being present in a concentration ranging from 2x10-9-5x10-6M, and (c) the phosphate donor being present in a concentration not exceeding 20 mM. The sensitivity of the method permits measurement of minute amounts of dTk, and the method can be used for e.g. diagnosis, prognostics and monitoring of diseases involving alterated ATP mediated dTk activity, such as cancers, tumors, and certain virus infections, or alterated CTP mediated dTk activity, such as HSV type 1, type 2, and VZV infections.